Eli Lilly has announced the launch of its weight-loss drug Zepbound in new 2.5 mg and 5 mg single-dose vials, significantly reducing the price to $399 and $549 per month, respectively, which is over 50% less than previous prices. The move aims to expand access to the drug for patients without insurance or those whose coverage does not include weight loss treatments. These vials differ from the previous auto-injector format, requiring patients to use a syringe for administration. The company emphasized that these changes will help meet the high demand and assist millions of adults with obesity. The announcement has impacted the stock prices of competitors in the weight-loss market, with shares of companies like Hims & Hers dropping in response. Eli Lilly's efforts come amid pressure from lawmakers to lower drug prices, highlighting the ongoing competitive dynamics in the obesity treatment sector.